Vrzal V, Matouch O
Bioveta, s.r.o., Ivanovice in Haná, Czech Republic.
Vet Med (Praha). 1996 Apr;41(4):107-11.
Ten young foxes were orally immunized with a "Rabies vaccine for oral immunization of foxes--LYSVULPEN por. a.u.v.," batch 69 10 93, commercially manufactured by the company Bioveta, s.r.o. at Ivanovice in Haná. The vaccine contained 1.8 x 10 of rabies vaccination virus, strain SAD-Bern, in a vaccination dose. Three foxes were used as control animals without vaccination. Blood samples were taken before the beginning of the experiment in all test foxes, and then in three-month intervals. The last blood samples were taken just before the beginning of a challenge experiment and two months after challenge in the foxes that survived. A challenge test was done in all foxes (vaccinated and nonvaccinated ones) a year after single oral immunization against rabies. Challenge virus was prepared from the salivary gland of a naturally infected fox living in the territory of the Czech Republic. Street virus was applied to each fox i.m. to a great depth to both masticatory muscles (musculus masseter) at a total dose of 10,000 MICLD50. The experimental animals were 60 days under observation. Tab. I shows the titers of virus-neutralizing rabies antibodies after oral immunization against rabies in all experimental foxes. Except fox no. 8, the formation of specific virus-neutralizing rabies antibodies was recorded in all animals after they had eaten vaccination baits. The antibodies were detected throughout the whole year of observation. Tab. II shows the results of challenge test. Out of the nine vaccinated foxes (fox no. 9 died before infection) only fox no. 8 died from rabies, the other treated foxes were protected from rabies (89% rate of protection). Tab. III presents the results of laboratory examination. Tetracycline was demonstrated in all treated foxes (a vaccination proof). Death due to rabies was demonstrated in control animals without vaccination and in fox no. 8. The results achieved in the Czech Republic for oral immunization of foxes against rabies with the vaccination strain SAD-Bern document very good efficacy of the vaccine manufactured by the company Bioveta, s.r.o., in Ivanovice in Haná since 1992. Oral immunization largely improved the infection situation in the Czech Republic. A total of 1,501 cases of rabies infection were recorded at the start of vaccination in 1989 while it was only 221 cases in 1994 (a decrease in then number of foci by 85%).
十只幼狐口服了由位于哈纳地区伊万诺维采的比奥韦塔股份公司（Bioveta, s.r.o.）商业化生产的“用于狐狸口服免疫的狂犬病疫苗——LYSVULPEN por. a.u.v.”，批次为69 10 93。该疫苗在一个接种剂量中含有1.8×10的狂犬病疫苗接种病毒，毒株为SAD - Bern。三只狐狸用作未接种疫苗的对照动物。在所有受试狐狸实验开始前采集血样，之后每隔三个月采集一次。最后一批血样在攻毒实验开始前采集，对于存活的狐狸，在攻毒后两个月采集。在单次口服狂犬病疫苗免疫一年后，对所有狐狸（接种和未接种的）进行了攻毒试验。攻毒病毒取自一只生活在捷克共和国境内自然感染狐狸的唾液腺。街毒以10,000 MICLD50的总剂量深部肌肉注射至每只狐狸的双侧咀嚼肌（咬肌）。对实验动物进行了60天的观察。表I显示了所有实验狐狸口服狂犬病疫苗免疫后狂犬病病毒中和抗体的滴度。除了8号狐狸外，所有动物在食用疫苗诱饵后均记录到特异性狂犬病病毒中和抗体的形成。在整个观察年中都检测到了抗体。表II显示了攻毒试验的结果。在九只接种疫苗的狐狸中（9号狐狸在感染前死亡），只有8号狐狸死于狂犬病，其他接受治疗的狐狸受到了狂犬病的保护（保护率为89%）。表III展示了实验室检查结果。在所有接受治疗的狐狸中均检测到四环素（证明接种成功）。未接种疫苗的对照动物和8号狐狸出现了因狂犬病导致的死亡。自1992年以来，在捷克共和国使用SAD - Bern疫苗株对狐狸进行口服狂犬病免疫所取得的结果证明了位于哈纳地区伊万诺维采的比奥韦塔股份公司生产的疫苗具有非常好的效果。口服免疫在很大程度上改善了捷克共和国的感染情况。1989年疫苗接种开始时共记录到1501例狂犬病感染病例，而在1994年只有221例（疫源地数量减少了85%）。
